US Biosimilars Will Get Regulatory Science Program, Supplement Timeline Changes In Next User Fee Agreement

 
• By Derrick Gingery
  
Sign outside of FDA's headquarters in White Oak, MD
The completed BsUFA III agreement includes supplement timeline improvements

More from Biosimilars

More from Products